Review of the Clinical Trial Failures of Nanomedicines Targeting Cancer
DOI:
https://doi.org/10.47611/jsrhs.v11i2.2607Keywords:
cancer, nanoparticles, analysis, clinical trials, BIND-014, CRLX-101, Abraxane, docetaxel, paclitaxel, camptothecinAbstract
Nanomedicine offers the potential to increase drug delivery to therapeutic targets while simultaneously reducing the instances of detrimental side effects. However, nanoparticles undergoing clinical trials are plagued with failures. One potential reason for such a high attrition rate is that proposed nanoparticle designs are based on models in preclinical trials which do not translate well to human clinical trials. Additionally, many cancer drugs suffer from a high excretion rate or, their dose-limiting toxicity prevents them from delivering an effective amount of therapeutic agent. Such failures are exemplified by BIND Therapeutics and Cerulean Pharma. This review article will attempt to detail the issues with model organisms encountered in translational research, as well as give a potential reason by comparing the failures of CRLX101, CRLX301, and BIND-014 with the success of Abraxane using the maximum tolerated dose (MTD) as a differentiating parameter.
Downloads
References or Bibliography
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., & Zarghami, N. (2013, August 1). Liposome: classification, preparation, and applications. National Center for Biological Information. Retrieved February 24, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599573/
Ballentine, C. (1981, June). Sulfanilamide Disaster. Food & Drug Administration. Retrieved February 24, 2022, from https://www.fda.gov/files/about%20fda/published/The-Sulfanilamide-Disaster.pdf
Barenholz, Y. (2012, June 10). Doxil®--the first FDA-approved nano-drug: lessons learned. PubMed. Retrieved February 24, 2022, from https://pubmed.ncbi.nlm.nih.gov/22484195/
Barenholz, Y. (2021, January 25). Doxil® — The First FDA-Approved Nano-Drug: From an Idea to a Product |. Taylor & Francis. Retrieved February 24, 2022, from
Bhardwaj, V. (2019). Recalcitrant Issues and New Frontiers in Nano-Pharmacology. Frontiers. Retrieved February 24, 2022, from https://www.frontiersin.org/articles/10.3389/fphar.2019.01369/full
Compound Summary - Camptothecin. (n.d.). National Center for Biological Information. Retrieved February 24, 2022, from https://pubchem.ncbi.nlm.nih.gov/compound/Camptothecine
Compound Summary - Docetaxel. (n.d.). PubChem. Retrieved February 24, 2022, from https://pubchem.ncbi.nlm.nih.gov/compound/Docetaxel
Cyclodextrins. (2015, September 21). American Chemical Society. Retrieved February 24, 2022, from https://www.acs.org/content/acs/en/molecule-of-the-week/archive/c/cyclodextrins.html
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., Noker, P., Yao, R., Labao, E., Hawkins, M., & Soon-Shiong, P. (2006, February 17). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. American Association for Cancer Research. Retrieved February 24, 2022, from https://aacrjournals.org/clincancerres/article/12/4/1317/283417/Increased-antitumor-activity-intratumor-paclitaxel
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010, October). Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. National Center for Biological Information. Retrieved February 24, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990151/
FORM 8-K. (2015, December 14). Securities and Exchanges Commission Archives. Retrieved February 24, 2022, from https://www.sec.gov/Archives/edgar/data/1385228/000119312515402021/d38880d8k.htm
Hodge, R. D. (2019, August 21). A recipe book for cell types in the human brain. Nature. Retrieved February 24, 2022, from https://www.nature.com/articles/s41586-019-1506-7?error=cookies_not_supported&code=e28987d9-cc0a-4d05-bc74-c8d8d0e2898a
Hoff, D. V. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., LoRusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., Zale, S. E., Summa, J. M., Youssoufian, H., & Sachdev, J. C. (2016, June 30). Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. American Association for Cancer Research. https://aacrjournals.org/clincancerres/article/22/13/3157/79244/Phase-I-Study-of-PSMA-Targeted-Docetaxel
Hongliang, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019, August 19). Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures. American Chemistry Society. Retrieved February 24, 2022, from https://pubs.acs.org/doi/10.1021/acs.accounts.9b00228
Hoogenboezem, E. N., & Duvall, C. L. (2019, July 27). Harnessing Albumin as a Carrier for Cancer Therapies. National Center for Biological Information. Retrieved February 24, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200408/
Horvath, C. J., & Milton, M. N. (2009, February 24). The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event? SAGE Journals. Retrieved February 24, 2022, from https://journals.sagepub.com/doi/10.1177/0192623309332986
Ingber, D. (2022, January 24). Human Organs-on-Chips. Wyss Institute. Retrieved February 24, 2022, from https://wyss.harvard.edu/technology/human-organs-on-chips/
Lazarus, D., Kabir, S., & Eliasof, S. (2012, April 15). Abstract 5643: CRLX301, a novel tumor-targeted taxane nanopharmaceutical. American Association for Cancer Research. Retrieved February 24, 2022, from https://aacrjournals.org/cancerres/article/72/8_Supplement/5643/582728/Abstract-5643-CRLX301-a-novel-tumor-targeted
Lühder, F., Huang, Y., Dennehy, K. M., Guntermann, C., Müller, I., Winkler, E., Kerkau, T., Ikemizu, S., Davis, S. J., Hanke, T., & Hünig, T. (2003, April 21). Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists. National Center for Biological Information. Retrieved February 24, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193880/
Magforce: Our Therapy. (2022, February 9). Magforce. https://www.magforce.com/en/home/our_therapy/
Markman, B., de Souza, P. L., Dees, E. C., Gangadhar, T. C., Cooper, A., Roohullah, A., Boolell, V., Zamboni, W.,
Murphy, C., Senderowicz, A. M., & Wang, H. (2016, May 20). A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors. Journal of Clinical Oncology. Retrieved February 24, 2022, from https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2526
Matsumura, Y., & Maeda, H. (1986, December). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. PubMed Commons. Retrieved February 24, 2022, from https://pubmed.ncbi.nlm.nih.gov/2946403/
Nemenov, D. G. (2017, February 21). Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis. ClinicalTrials.Gov. Retrieved February 24, 2022, from https://clinicaltrials.gov/ct2/show/study/NCT01990157
Pappa, T., & Refetoff, S. (2017). Human Serum Albumin - an overview | ScienceDirect Topics. ScienceDirect. Retrieved February 24, 2022, from https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/human-serum-albumin
Prabhakar, U., Maeda, H., & Jain, R. K. (2014, February 6). Challenges and key considerations of the enhanced permeability and retention (EPR) effect for nanomedicine drug delivery in oncology. National Center for Biological Information. Retrieved February 24, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916009/
Rafiyath, S. M. (2012, April 23). Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis - Experimental Hematology & Oncology. BioMed Central. Retrieved February 24, 2022, from https://ehoonline.biomedcentral.com/articles/10.1186/2162-3619-1-10
Raunio, H. (2011, June 30). In Silico Toxicology – Non-Testing Methods. National Center for Biological Information. Retrieved February 24, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129017/
Soares, S. (2018, August 20). Nanomedicine: Principles, Properties, and Regulatory Issues. Frontiers in Chemistry. Retrieved February 23, 2022, from https://www.frontiersin.org/articles/10.3389/fchem.2018.00360/full
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006, September 7). Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. New England Journal of Medicine. Retrieved February 24, 2022, from https://www.nejm.org/doi/full/10.1056/nejmoa063842
Sztandera, K., Gorzkiewicz, M., & Klajnert-Maculewicz, B. (2018, November 19). Gold Nanoparticles in Cancer Treatment. American Chemistry Society. Retrieved February 24, 2022, from https://pubs.acs.org/doi/full/10.1021/acs.molpharmaceut.8b00810
UPDATED: Cerulean Pharma’s lead nanodrug crashes in lung cancer study. (2013, March 22). Fierce Biotech. Retrieved February 24, 2022, from https://www.fiercebiotech.com/venture-capital/updated-cerulean-pharma-s-lead-nanodrug-crashes-lung-cancer-study
Urry, L., Cain, M., Wasserman, S., Minorsky, P., & Reece, J. (2016). Campbell Biology (Campbell Biology Series) (11th ed.). Pearson.
Veronese, F. M., & Mero, A. (2018, July 27). The impact of PEGylation on biological therapies. National Center for Biological Information. Retrieved February 24, 2022, from https://pubmed.ncbi.nlm.nih.gov/18778113/
Weiss, G. J., Chao, J., Neinhart, J. D., Ramanathan, R. K., Basset, D., Neinhart, J. A., Choi, C. H. J., Chow, W.,
Chung, V., Forman, S. J., Garmey, E., Hwang, J., Kalinoski, D. L., Koczywas, M., Longmate, J., Melton, R. J., Morgan, R., Oliver, J., Peterkin, J. J., . . . Yen, Y. (2013, February 9). First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. SpringerLink. Retrieved February 24, 2022, from https://link.springer.com/article/10.1007/s10637-012-9921-8?error=cookies_not_supported&code=6bd3e7c7-fd90-4bb7-a0d2-52011467c9f0#citeas
Wilhelm, S. (2016, September 13). Evaluation of nanomedicines: stick to the basics. Nature. Retrieved February 24, 2022, from https://www.nature.com/articles/natrevmats201614?error=cookies_not_supported&code=10b07acf-b495-4e54-923f-937fcb8d3b9a
Young, C., Schluep, T., Hwang, J., & Eliasof, S. (2011, March). CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development. National Center for Biological Information. Retrieved February 24, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182091/
Yuan, F., Dellian, M., Leunig, M., Fukumura, D., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995, September 1). Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. PubMed. Retrieved February 24, 2022, from https://pubmed.ncbi.nlm.nih.gov/7641188/
Published
How to Cite
Issue
Section
Copyright (c) 2022 Shourish Mukherjee; Alexander Honkala, Benjamin Rolnik
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
